Array BioPharma Inc. (NASDAQ:ARRY) Director Lunsen Gil J. Van sold 21,500 shares of the business’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $12.94, for a total value of $278,210.00. Following the completion of the transaction, the director now directly owns 34,297 shares in the company, valued at approximately $443,803.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of Array BioPharma Inc. (ARRY) opened at $13.14 on Friday. The firm has a market capitalization of $2,537.71, a price-to-earnings ratio of -17.76 and a beta of 1.91. Array BioPharma Inc. has a 52-week low of $6.73 and a 52-week high of $14.40. The company has a debt-to-equity ratio of 0.54, a quick ratio of 5.43 and a current ratio of 5.43.
Array BioPharma (NASDAQ:ARRY) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.22). The company had revenue of $29.75 million during the quarter, compared to the consensus estimate of $33.74 million. Array BioPharma had a negative return on equity of 158.70% and a negative net margin of 89.30%. The firm’s quarterly revenue was down 24.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.20) earnings per share. research analysts forecast that Array BioPharma Inc. will post -0.99 EPS for the current year.
A number of equities analysts have commented on the company. Cantor Fitzgerald set a $15.00 price objective on Array BioPharma and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. Zacks Investment Research lowered Array BioPharma from a “hold” rating to a “sell” rating in a research note on Thursday, January 4th. BidaskClub raised Array BioPharma from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Jefferies Group boosted their price objective on Array BioPharma to $13.00 and gave the stock a “buy” rating in a research note on Friday, December 22nd. Finally, SunTrust Banks reissued a “buy” rating and issued a $16.00 price objective on shares of Array BioPharma in a research note on Wednesday, November 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the stock. Array BioPharma has a consensus rating of “Buy” and an average price target of $14.10.
Hedge funds have recently added to or reduced their stakes in the company. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Array BioPharma during the second quarter worth $110,000. Ameritas Investment Partners Inc. raised its position in shares of Array BioPharma by 7.2% during the second quarter. Ameritas Investment Partners Inc. now owns 15,148 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 1,012 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Array BioPharma during the third quarter worth $146,000. Raymond James Financial Services Advisors Inc. raised its position in shares of Array BioPharma by 71.9% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 18,317 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 7,661 shares during the last quarter. Finally, Prudential Financial Inc. raised its position in shares of Array BioPharma by 9.1% during the second quarter. Prudential Financial Inc. now owns 18,957 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 1,580 shares during the last quarter. Institutional investors own 98.13% of the company’s stock.
WARNING: “Array BioPharma Inc. (ARRY) Director Sells $278,210.00 in Stock” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/20/array-biopharma-inc-arry-director-sells-278210-00-in-stock.html.
Array BioPharma Company Profile
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).
Receive News & Ratings for Array BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.